First NHS UK Site to Begin Treating Participants with New Alzheimer’s Investigational Product

The Memory Assessment & Research Centre (MARC) has become the first NHS site in the UK to begin treating participants with an investigational treatment being evaluated as part of a global clinical trial in people with early Alzheimer’s disease. This international Phase 2 study aims to determine whether the investigational medication can slow disease progression by targeting tau protein changes in the brain.

Why This Research Is Being Done

Alzheimer’s disease leads to progressive memory loss, communication difficulties, and a decline in daily functioning. One of the key drivers of this deterioration is the accumulation and spread of tau protein within the brain.

Current treatments mainly offer symptomatic relief and do not address the underlying disease process. The investigational medication is an anti‑tau antibody designed to target tau‑related changes directly. This study seeks to understand whether modifying tau pathology can impact the progression of early Alzheimer’s disease.

About the Study

The study is a Phase 2, randomised, placebo‑controlled, double‑blind clinical trial assessing both the safety and efficacy of the investigational medication in early Alzheimer’s disease.

• Approx. 340 adults aged 50–85

• Diagnosed with mild cognitive impairment (MCI) or mild Alzheimer’s dementia

• Monthly intravenous infusions of either the investigational medication or placebo for around two years

• Participants undergo:

  • PET imaging to track tau levels

  • Cognitive testing

  • Laboratory assessments

  • Measures of daily functioning

Further details can be found at the study’s official summary page.

Quote from Principal Investigator

“I am delighted that we have successfully recruited the first NHS UK participants into this study. Bringing this trial to MARC provides a chance for people living with memory difficulties and their families to access the latest research opportunities. We are immensely grateful to the volunteers whose participation makes any kind of research possible; their contribution is vital if we are going to develop meaningful interventions for Alzheimer’s disease.” - Dr Brady McFarlane

Expected Impact

The results of this clinical trial may shape future treatment approaches and care for people and families affected by dementia.